BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BiO2 Medical, Inc. Announces First in Man Clinical Study


3/28/2012 10:21:58 AM

SAN ANTONIO, March 27, 2012 /PRNewswire/ -- BiO2 Medical, Inc., a Texas based medical device manufacturer with manufacturing operations in Golden, Colorado, is proud to announce the first in man clinical study for the Angel Catheter. The clinical study is being conducted under IRB approval at two medical centers in Medellin, Colombia, Clinica Las Americas, and Hospital Pablo Tobon Uribe. As of today, eight critically ill patients have been enrolled in the study.

Dr. Cadavid and Dr. Gil, the principal investigators in the first in man clinical study, commented on the ease of bedside insertion of the Angel Catheter in a procedure that resembles a routine central venous catheter placement. Both principal investigators feel that the Angel Catheter fills an important clinical need for an Inferior Vena Cava filter designed for use in critically ill patients at high risk of pulmonary embolism (PE).

Dr. John A. Kaufman from the Dotter Interventional Institute and a member of BiO2 Medical's clinical advisory board said, "This marks an important advance in the management of critically ill patients everywhere. The ability to protect from pulmonary embolism and resuscitate with one device is unique."

This important milestone for the company will provide vital data regarding the safety of the Angel Catheter in a clinical setting, which will be instrumental in facilitating clinical adoption of the device. BiO2 Medical has been working closely with Pharmaceutical Product Development, Inc. (PPD), a contract research organization (CRO) that provides expertise in clinical development, management, and post approval services, in the design and execution of this first in man clinical study.

BiO2 Medical's Chairman and Chief Executive Officer, Christopher E. Banas, commented on the initiation of the clinical study, "We are proud to be providing a lifesaving technology for critically ill patients at risk of PE, and this study demonstrates that this device is safe for use." For more information regarding BiO2 Medical, and the Angel Catheter please visit www.bio2medical.com.

SOURCE BiO2 Medical, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->